Skip to content

Drug interactions

Daunorubicin + Ponatinib

Severity: Major

Daunorubicin and Ponatinib: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Ponatinib inhibits P-gp and BCRP and may increase daunorubicin exposure. Both agents carry cardiac toxicity and myelosuppression, so combined effects may be significant.

What this interaction means in plain words

Daunorubicin and Ponatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Daunorubicin belongs to Oncology; Ponatinib belongs to Oncology.

Evidence level: Low

Why it happens

Ponatinib inhibits P-gp and BCRP efflux, with additive cardiovascular and hematologic toxicity.

What to do

Monitor cardiac function (including LVEF) and blood counts closely; reduce daunorubicin dose if toxicity appears.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Daunorubicin and Ponatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Daunorubicin with Ponatinib?

MediHelp rates the interaction as major. Daunorubicin and Ponatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Ponatinib inhibits P-gp and BCRP and may increase daunorubicin exposure. Both agents carry cardiac toxicity and myelosuppression, so combined effects may be significant.

How serious is the interaction between Daunorubicin and Ponatinib?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor cardiac function (including LVEF) and blood counts closely; reduce daunorubicin dose if toxicity appears.

What other medicines interact with Daunorubicin?

MediHelp also lists interactions of Daunorubicin with, for example, Adenovirus types 4 and 7 live, Belatacept, Cyclosporine. The full list is on the Daunorubicin page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in